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A four compartment mechanistic mathematical model is developed for the pharmacoki-
netics  of the commonly used anti-malarial drug artesunate and its principle metabolite
dihydroartemisinin following oral administration of artesunate. The model is structurally
unidentiﬁable  unless additional constraints are imposed. Combinations of mechanistically
derived  constraints are considered to assess their effects on structural identiﬁability and on
model ﬁts. Certain combinations of the constraints give rise to locally or globally identiﬁable
model  structures.
Initial validation of the model under various combinations of the constraints leading
to  identiﬁable model structures was performed against a dataset of artesunate and dihy-
droartemisinin  concentration–time proﬁles of 19 malaria patients. When all the discussedtructural identiﬁability
arameter estimation
ensitivity  analysis
constraints  were imposed on the model, the resulting globally identiﬁable model structure
was  found to ﬁt reasonably well to those patients with normal drug absorption proﬁles.
However,  there is wide variability in the ﬁtted parameters and further investigation is warr-
e Au
artemisinin  monotherapies, will assist in delaying artemisininanted.
©  2013 Th
.  Introduction
alaria is a parasitic disease that has affected humans and
nimals  for thousands of years [1]. Even now in the 21st cen-
ury,  the most deadly strain Plasmodium falciparum infects 200
illion people and causes over half a million deaths every
ear,  with young children being most severely affected [2].
Artemisinin  and its derivatives have been used as anti-
alarials with increasing frequency since the 1990s [3]. They
re  the most rapidly acting drugs out of the currently available
nti-malarials [4], reducing the parasite biomass ∼10, 000-fold
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per asexual life cycle [5,4]. They are well-tolerated and pro-
duce  few side-effects [4], and as such form the core part
of  the World Health Organisation recommended ﬁrst-line
treatment for many  patients: artemisinin-based combination
therapies [2]. Artemisinins remain as the most effective drugs
to  which malaria has not yet developed widespread resistance,
though  resistance has been conﬁrmed in some regions [4]. It
is hoped that use of these combination therapies, in favour of
Open access under CC BY license.resistance to ensure artemisinins continue to remain effec-
tive  against multi-drug resistant malaria [4]. Meanwhile, there
remains  an urgent need to develop new antimalarials [6].
cess under CC BY license.
 m s i2  c o m p u t e r m e t h o d s a n d p r o g r a
However, the behaviour of current artemisinins is still not
fully  understood; debate remains concerning their mecha-
nism  of action [7,8] and stage-speciﬁc effects [9]. One theory
is  that artemisinins decompose when activated by iron that
has  accumulated in malaria infected red blood cells, form-
ing  free radicals which then damage the parasites [10]. Thus
in  this theory, the anti-malarial action also acts as a route of
elimination  for artemisinins.
Further,  recrudescence is frequently observed with the cur-
rently  adopted dosing regimens [11], which have been derived
largely  empirically [4]. This recrudescence may  be attributed
to  either resistant or arrested/dormant parasites, or the drug
concentrations in blood falling below their effective levels, but
such issues have not yet been fully characterised [9].
The  blood plasma concentration–time proﬁles and thus
the  pharmacokinetics of artemisinins have been shown to
display  high inter-individual variability in the majority of
studies.  Further understanding of the pharmacokinetics and
pharmacodynamics of artemisinins may  assist in informing
more  effective dosing regimens, as well as the development of
improved  antimalarials. This work focusses on the pharma-
cokinetics because a pharmacodynamic model should build
on  a well-suited pharmacokinetic model.
Artesunate (hereafter ARS) is the most frequently used
artemisinin derivative, and is rapidly and almost entirely con-
verted  to dihydroartemisinin (hereafter DHA) in vivo, mostly by
plasma esterases and liver cytochrome P450 CYP2A6 [12–14].
DHA  is the most active of all artemisinin derivatives, with
activity  approximately 1.4 times that of ARS [15].
ARS is water soluble, facilitating its absorption [16] (usu-
ally  assumed to be fast, efﬁcient and ﬁrst-order [12]). Its
rapid  hydrolysis into the more  active metabolite means that
although  ARS may  make a signiﬁcant contribution to parasite
kill  [17], it is often referred to as a pro-drug for DHA [3], and
some  researchers take the viewpoint that it is therefore not
necessary  to model the parent drug. DHA is also rapidly elim-
inated,  again either through activation by infected red blood
cells  or through further metabolism (e.g. glucuronidation [4]),
but  the metabolites of DHA are inactive [18].
Many of the results and methods of studies involving ARS
and  DHA are summarised in Morris et al. [12], so no attempt is
made to list them here. Instead, a brief discussion of existing
models  for artemisinin-class drugs in general, their features
and  the analyses conducted on them is provided in the next
subsection.
1.1.  Existing  models
Many  existing pharmacokinetic studies for artemisinins have
been  conducted over the last couple of decades, and have
successfully provided some insights into the absorption, elim-
ination and/or multiple dosing behaviour of these drugs,
and  the covariates that inﬂuence these. Some studies have
restricted  their interest to either healthy subjects, uncompli-
cated  malaria, or severe malaria, and either children, adults or
pregnant women, while others have been designed speciﬁcally
to  consider the differences between some of these groups.
Each  study focusses on a speciﬁc artemisinin derivative or
derivatives,  and a speciﬁc route or routes of administration,
either alone or in combination with other antimalarial agents. n b i o m e d i c i n e 1 1 2 ( 2 0 1 3 ) 1–15
Of those that used modelling rather than non-
compartmental approaches, some have been used to analyse
the  effects of differing dosing regimens in different contexts,
including cases where the malaria has developed resistance
to  this class of drugs [19]. They range from being very simple,
e.g.  with linear absorption and exponential elimination as in
Saralamba et al. [19], to being quite complicated, e.g. involv-
ing  9 compartments as in Gordi et al. [20], and of various
complexities in between, e.g. 4 compartments as in Tan et al.
[21].
However, such models have not been analysed to deter-
mine  if they are structurally identiﬁable. The importance of
knowing  the structural identiﬁability of models will be reit-
erated  in this paper. Indeed, Karunajeewa et al. [22] use a
three-compartment model based on mechanistic principles
but  experience problems obtaining parameter estimates, per-
haps  due to structural identiﬁability issues. In many  of the
more  complicated models, there are even more  unknown
parameters and many  of these have to be assigned ﬁxed values
in  order to estimate the remaining parameters successfully
(again perhaps due to structural identiﬁability issues). In those
cases,  the selection of the parameters to ﬁx and what values to
use can be somewhat arbitrary and the effects of using other
values  is not always explored or reported.
When processes involved in the system being modelled
are  not well understood, it can be informative to perform
model selection based on comparing a relative goodness of
ﬁt  statistic for a variety of structural models, and indeed this
approach  is used to various extents for the pharmacokinetic
models used for artemisinins in the literature. However, when
information  is known about the processes and mechanisms
involved, models selected in this way  can be less useful than
models  of process [23], and of course different models must be
used for different observational situations (e.g. Gordi et al. [20]
measure  drug concentrations in saliva samples as opposed
to  the more  common use of plasma samples, and so uses a
model  tailored for that situation). To be fully certain of model
appropriateness, ﬁts should be reported and validated on an
individual patient basis in addition to any population lev-
els  of interest. (If a mixed-effects/hierarchical model is used,
this  means estimating the subject-speciﬁc deviation from the
mean  parameters.) This can help to determine whether or not
there  are key features of the data that are missed due to the
structure  of the model employed, which may  go unnoticed if
only population data are considered. However, pharmacoki-
netics on an individual patient basis are understandably of
less  interest than at population levels, and so attention typi-
cally  focusses only on population ﬁts.
In summary, there are currently no known coupled mecha-
nistic  pharmacokinetic models for artemisinin derivatives and
corresponding  metabolites in vivo, with observations made of
the  blood plasma concentrations of the administered deriva-
tives  and their metabolites, that have either been analysed in
a structural identiﬁability sense or validated on an individual
patient  basis.2.  The  model
A relatively simple coupled mechanistic model was  developed
for  the pharmacokinetics of orally-administered ARS and its
c o m p u t e r m e t h o d s a n d p r o g r a m s i n
1 3
2 4
bDδ(t)
y2(t) = α2q4(t)y1(t) = α1q2(t)
k21
k31
k43
k42
ke2
ke3
ke4
Fig. 1 – System diagram of the general compartmental
m
p
c
e
c
l
a
c
a
m
e
t
p
d
o
(
d
a
t
o
i
(
m
E
c
b
a
c
(
u
t
m
o
e
w
p
o
p
podel
rinciple metabolite DHA, for situations where blood plasma
oncentrations of both are observed, and is depicted in Fig. 1.
It  consists of four linked compartments, with the par-
nt  drug and its metabolite each represented by two
ompartments: an absorption (gut) compartment and a circu-
ation/plasma compartment. The absorption compartments
ccount for the delay in the drug and metabolite reaching the
irculation  (and site of measurement) due to the oral route of
dministration.
This  differs structurally from the generic parent-
etabolite model with oral dose described by Cheung
t  al. [24] (analysed for structural identiﬁability and applied
o  dextromethorphan and dextrophan), which uses an extra
eripheral  compartment for the parent drug and has a
irect  ﬂow from its single absorption compartment to the
bserved/central metabolite compartment.
The administered oral dose of ARS is considered as a bolus
impulsive) input into its absorption compartment (1 in the
iagram).  To account for bioavailability, a fraction b of the
dministered dose D is assumed to reach the systemic circula-
ion.  The dose D is prescribed in proportion to the body weight
f  the patient, and so taken in units of nmol per kg.
Once  in the system, ARS is either irreversibly metabolised
nto DHA (compartment 3) prior to reaching the circulation
compartment 4), or is absorbed into the circulation (compart-
ent  2) and subsequently metabolised (compartment 4 again).
limination  can occur from any compartment except the input
ompartment,  and can be caused by either excretion from the
ody  or further metabolism into inactive metabolites which
re  not of interest.
Observations are made of the drug concentrations in the
irculation compartments, with observation gains ˛1 for ARS
y1) and ˛2 for DHA (y2). These parameters incorporate the vol-
mes  of distribution of the respective drugs. As is standard for
he purposes of assessing the identiﬁability of the structural
odel,  it is assumed that observations are made continually
ver  the entire inﬁnite time horizon, and are made without
rror.  These two assumptions are relaxed later when dealing
ith  the problem of parameter estimation from data.
Note  that because metabolism of ARS into DHA takeslace  in the liver as well as in esterases, metabolism can
ccur  before presentation in the observed circulation com-
artments. Indeed, in concentration–time proﬁles of malaria
atients  (e.g. those analysed in this work), large quantities of b i o m e d i c i n e 1 1 2 ( 2 0 1 3 ) 1–15 3
DHA  are observed in the blood plasma prior to those of ARS,
which  cannot be attributed solely to being artefacts of differ-
ing  observation gains (or otherwise to quantiﬁcation limits).
Hence,  the presence of compartment 3 is crucial to capture
the  metabolism-before-absorption route that ARS can take.
The  differential equation characterisation of the model is
given,  for t ∈ [0, ∞) describing the time in hours since drug
administration, by
⎧⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎩
q′(t) = Aq(t) + Bu(t)
q(0+) =  q0
y(t) = Cq(t).
(1)
Here, q = (q1 q2 q3 q4)T represents the state vector of the
system model, where each qi denotes the quantity of the
respective drug in compartment i, u(t) = (Dı(t) 0 0 0)T denotes
the model input and q0 = (0 0 0 0)T the initial condition, y
denotes the vector-valued observation function, and the
model  matrices are
A =
⎛
⎜⎜⎜⎜⎝
−(k21 + k31) 0 0 0
k21 −(k42 + ke2) 0 0
k31 0 −(k43 + ke3) 0
0  k42 k43 −ke4
⎞
⎟⎟⎟⎟⎠ , (2a)
B =
⎛
⎜⎜⎝
b
0
0
0
⎞
⎟⎟⎠ , C =
(
0 ˛1 0 0
0 0 0 ˛2
)
. (2b)
Note that there are different ways  to parameterise u, q0 and
B.  The parameterisation used here has been chosen as it more
clearly  corresponds to the mechanistic concepts.
Due to the difference in the molecular weights of the parent
drug  and the metabolite, the qi are considered in units of molar
mass,  per kilogram of patient body weight (nmol/kg). Observa-
tions,  which are concentrations, are assumed to be in units of
nmol/l.  The observation gains ˛1 and ˛2 therefore have units of
kg/l,  but the volumes of distribution are generally assumed to
scale approximately linearly with patient body weight, hence
the  reason that the dosing is calculated in those terms.
All  ﬂows (absorption, metabolism and elimination) are
assumed  to be ﬁrst-order and linear, with rate constants kij
(denoting the ﬂow rate constant to compartment i from com-
partment  j, or to the environment when i = e) time-invariant
and speciﬁed in units of per hour (which are standard units for
artemisinin  drugs). Note that conversion into inactive unmea-
sured  metabolites and excretion from the body are considered
as  ﬂows to the environment with respect to the system model.
The  system of equations (1), with u(t) and q0 as described
above, can easily be solved analytically to yield:
q(t) = bDeAt, y(t) = Cq(t). (3)
 m s i4  c o m p u t e r m e t h o d s a n d p r o g r a
The solution for the state variables is thus
q1(t) = bDe−(k21+k31)t
q2(t) =
bDk21
(
e−(k42+ke2)t − e−(k21+k31)t
)
k21 + k31 − k42 − ke2
q3(t) =
bDk31
(
e−(k43+ke3)t − e−(k21+k31)t
)
k21 + k31 − k43 − ke3
q4(t) = bD
(
e−(k21+k31)t
k221k42 + k31k43(k31 − k42 − ke2) + k21(k31(k42 + k43) − k42(k43 + ke3))
(k21 + k31 − k42 − ke2)(k21 + k31 − k43 − ke3)(k21 + k31 − ke4)
− e
−(k42+ke2)tk21k42
(k21 + k31 − k42 − ke2)(k42 + ke2 − ke4)
− e
−(k43+ke3)tk31k43
(k21 + k31 − k43 − ke3)(k43 + ke3 − ke4)
+ e
−ke4 t(k31k43(k42 + ke2 − ke4) + k21k42(k43 + ke3 − ke4))
(k21 + k31 − ke4)(k42 + ke2 − ke4)(k43 + ke3 − ke4)
)
.
(4)
3.  Structural  identiﬁability
Before attempting to apply this model to real data for parame-
ter  estimation, it is necessary to check that all the parameters
are  theoretically identiﬁable from “perfect data” (noise-free
data  available over the entire inﬁnite time horizon assum-
ing  no model misspeciﬁcation), in the sense that they can
either  be uniquely determined or there are only a countable
number of alternative parameter combinations with identi-
cal  input/output structure. This is the structural identiﬁability
property, and is an important property to check in order to
understand  what kinds of inferences can validly be made
about  the parameters in the model. For an unidentiﬁable
model, a good ﬁt to data does not imply that the estimated
parameters have any connection to the intended interpreta-
tions,  which may  invalidate model predictions and in turn
cause  important decisions in terms of dosing regimens to be
made incorrectly.
Let  p denote the vector of unknown parameters in the
model.  Take
p =
(
b k21 k31 k42 k43 ke2 ke3 ke4 ˛1 ˛2
)T
, (5)
where the feasible parameter space is  : = (0, ∞)n  p, with
n  = 10 denoting the number of unknown parameters.
The observation function y is now written y(· , p) to empha-
sise  its dependence on the unknown parameters.
3.1.  Structural  identiﬁability  deﬁnitions
Structural identiﬁability is the measure theoretic concept of
local  injectivity of the observation function with respect to the
model  parameters, excepting sets of parameter values with
measure  zero.
A  component parameter pi of p is said to be n b i o m e d i c i n e 1 1 2 ( 2 0 1 3 ) 1–15
• structurally locally identiﬁable (SLI) iff for almost every
p  ∈ , there exists a neighbourhood N(p) ⊆  of vectors
around p such that
if p¯∈  N(p) and y(·, p) = y(·, p¯)
then p¯i = pi;
(6)
• structurally unidentiﬁable (SUI) otherwise.
If N(p) =  can be used in (6) for almost every p, then pi is also
said  to be structurally globally identiﬁable (SGI).
The structural identiﬁability of the whole model is deﬁned
in  terms of the structural identiﬁability of the unknown
parameters as follows:
•  The model is structurally locally identiﬁable iff all parameters
in  p are at least structurally locally identiﬁable;
• The model is structurally unidentiﬁable iff any of the param-
eters  in p are structurally unidentiﬁable.
If all the parameters in the model are also structurally glob-
ally  identiﬁable then the model itself is said to be structurally
globally identiﬁable.
Note  that structural identiﬁability depends on each of the
feasible  parameter space, the system model structure, the
observations and the inputs.
3.2.  Analysis  for  present  model
The structural identiﬁability of this model was  analysed using
the  Laplace transform approach [25], one of the most com-
monly  used methods for linear time-invariant systems.
This  method considers the Laplace transforms of the
observation functions after eliminating the state variables.
It  extracts the coefﬁcients of the resulting expressions once
written  in a standard form, with common factors in each
respective numerator and denominator cancelled. These
coefﬁcients are assembled in a vector (p) as an “exhaustive
summary” of observational parameters [26]. The injectivity
condition of the full observation function vector is equiva-
lent  to that of the exhaustive summary, and the latter has the
advantage  of being easier to work with.
The Laplace transforms of the observation functions
y1(· , p) and y2(· , p) are given (in their simplest forms), for s ∈ C,
by
Y1(s, p) = 1(p)
s2 + 2(p)s + 3(p)
,  (7a)
Y2(s, p) = 4(p)s + 5(p)
s4 + 6(p)s3 + 7(p)s2 + 8(p)s + 9(p)
,  (7b)
where the coefﬁcients depending on p form the exhaustive
summary and are given by
1(p) = ˛1bDk21 (8a)2(p) = k21 + k31 + k42 + ke2 (8b)
3(p) = (k21 + k31)(k42 + ke2) (8c)
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4(p) = ˛2bD(k21k42 + k31k43) (8d)
5(p) = ˛2bD(k21k42(k43 + ke3) + k31k43(k42 + ke2)) (8e)
6(p) = k21 + k31 + k42 + k43 + ke2 + ke3 + ke4 (8f)
7(p) = (k21 + k31)(k42 + k43 + ke2 + ke3 + ke4) + ke4(k42 + k43
+ ke2 + ke3) + (k42 + ke2)(k43 + ke3) (8g)
8(p) = ke4(k21(k42 + k43 + ke2 + ke3) + k31(k42 + k43 + ke2 + ke3)
+ (k42 + ke2)(k43 + ke3)) + (k21 + k31)(k42 + ke2)(k43 + ke3) (8h)
9(p) = ke4(k21 + k31)(k42 + ke2)(k43 + ke3). (8i)
Using the Laplace transform approach, the structural (local)
dentiﬁability problem is to determine whether, for generic p,
he only solution (in a neighbourhood of p) to the system of
quations
1(p) = 1(p¯) (9a)
2(p) = 2(p¯), (9b)
(9c)
9(p) = 9(p¯) (9d)
s
 = p¯. (10)
The symbolic computer package Maple (version 16) was
sed  to solve this system of equations. Mathematica (ver-
ion  8.0.1) failed to solve this system of equations on an
ntel  Core i5 2.40 GHz machine with 2.8 GB of memory  before
xhausting the available memory  after 30 min, whereas Maple
omfortably  solved the system within 2 min  on the same
achine.
It  is readily observed (e.g. from the Laplace coefﬁcients) that
,  ˛1 and ˛2 are not structurally identiﬁable individually, since
hey  appear only as the products b˛1 and b˛2. In what follows,
˛1 and b˛2 are therefore considered to be combined param-
ters.  Hence, the set of unknown parameters is now taken as
 = ( k21 k31 k42 k43 ke2 ke3 ke4 b˛1 b˛2 )
T
,
so with n = 9 unknown parameters) and the structural identi-
ability  analysis proceeds in this setting.
Solving the system of equations (3.2) reveals that ke4 is
LI  with either ke4 = ke4 or ke4 = k43 + ke3, and all other model
arameters are SUI. As there is little point working with a SUI
odel,  the following additional assumptions were  therefore
onsidered to see if they constrain the system model to be
tructurally  identiﬁable: Other studies have reported apparent volumes of distribu-
tion  for ARS and DHA following oral administration of ARS.
In  particular, Morris et al. [12] report the median volume b i o m e d i c i n e 1 1 2 ( 2 0 1 3 ) 1–15 5
of distribution for ARS at 6.8 l/kg and 1.55 l/kg for DHA in
malaria  patients (though these are noted to vary signiﬁ-
cantly  relative to severity of infection). Such information
can be used to treat the ratio of the observation gains as
known;  that is, r : = ˛2/˛1 is known (˛1 =  ˛ and ˛2 = r˛, say).
Using the above information from Morris et al. [12], this
would  give r = 4.387 (the observation gain for DHA is larger
because  it has the smaller volume of distribution);
2 There is no known reason to suggest that the metabolism
of  the ARS occurs at signiﬁcantly different rates before
and  after absorption, so it might be valid to consider the
metabolism rate constants to be equal: k31 = k42;
3 ARS is almost entirely converted to DHA (there are little
excreted traces of ARS or its other metabolites), so it may  be
reasonable  to assume that the elimination rate parameter
ke2 = 0;
4 Absorption of the metabolite is rapid, thus its elimination
may  be negligible before it is absorbed, i.e. ke3 = 0.
Note that when constraints of this sort are imposed on
parameters, the corresponding models are considered to be
structurally distinct; structural identiﬁability is concerned
with  the behaviour of almost all parameter values, and these
assumptions may  mean that previously null sets now have
strictly  positive measure.
Each  combination of these four assumptions was  assessed
using  the same methods as previously, and the structural
identiﬁability results are tabulated in Table 1. It can be seen
that  applying just one of the additional constraints does not
improve  the structural identiﬁability for the majority of the
parameters.  Applying any combination of two constraints
except ˛2/˛1 = r and ke2 = 0 constrains all the parameters to be
at  least structurally locally identiﬁable. Applying any combi-
nation  of three of the assumptions constrains the model to
be  structurally globally identiﬁable. The assumption (2) that
k31 = k42 seems to be the weakest in terms of improving struc-
tural  identiﬁability.
Parameter estimates will be obtained with all four assump-
tions  imposed, as it the strongest situation in terms of
structural identiﬁability, and the fewer degrees of freedom
will  aid in more  precise estimation of parameters. Parameter
estimates will also be obtained with other structurally identi-
ﬁable  combinations of assumptions, to assess the sensitivity
to  the assumptions and to ensure that the system is not over-
constrained.
4.  Parameter  estimation
4.1.  Data
The authors had access to a dataset of 19 malaria patients
from  a study carried out at the Department of Clinical
Tropical Medicine, Faculty of Tropical Medicine, Mahidol Uni-
versity,  Bangkok, 10400, Thailand. Patients were  selected
based  on a diagnosis of adult non-severe P. falciparum malaria
with  a parasite count less than 10,000 parasites per microlitre
of  blood. The patients were  each administered 2 mg/kg arte-
sunate  in fractions of 50 mg  oral tablets (body weights not part
of  the dataset) twice daily for three days, in combination with
6  c o m p u t e r m e t h o d s a n d p r o g r a m s i n b i o m e d i c i n e 1 1 2 ( 2 0 1 3 ) 1–15
Table 1 – Structural identiﬁability analysis results
Assumptions Structural identiﬁability results
˛2
˛1
= r, r known k31 = k42 ke2 = 0 ke3 = 0 k21 k31 k42 k43 ke2 ke3 ke4 b˛1 b˛2 b˛
0 0 0 0 U U U U U U L U U –
0 0 0 1 U U U L U – L U U –
0 0 1 0 U U L U – U L U U –
0 0 1 1 L L L L – – L L L –
0 1 0 0 U – U U U U L U U –
0 1 0 1 L – L L L – L L L –
0 1 1 0 G – G L – L L G L –
0 1 1 1 G – G G – – G G G –
1 0 0 0 U U L U L U L – – U
1 0 0 1 L L L L L – L – – L
1 0 1 0 U U G U – U G – – U
1 0 1 1 G G G G – – G – – G
1 1 0 0 L – L L L L L – – L
1 1 0 1 G – G G G – G – – G
1 1 1 0 G – G G – G G – – G
1 1 1 1 G – G G – – G – – G
ions 
lobalThe applicable parameters under any combination of the assumpt
unidentiﬁable (U), structurally locally identiﬁable (L) or structurally g
1800 mg  fosmidomycin and 750 mg  azithromycin which are
antibiotics  and not considered relevant to the modelling. Food
was restricted for the ﬁrst hour after dosing.
The data consist of ARS and DHA concentrations (provided
in  units of ng/ml but converted to nmol/l prior to analysis)
from  assayed blood plasma samples over a time course of 12 h.
Blood plasma samples were  drawn from the patients imme-
diately  after administration of the ﬁrst dose on the ﬁrst day,
15  min  after, 30 min  after, 1 h after, 1.5 h after, 2 h after, 3 h after,
4  h after, 6 h after, 8 h after and 12 h after administration of the
ﬁrst  dose on the ﬁrst day. No samples were taken for subse-
quent  doses or on subsequent days and so cannot be included
in  the modelling.
Samples were analysed to determine their ARS and DHA
concentrations using tandem liquid chromatography-mass
spectrometry (on a Thermo Fisher Quantum Access Triple
Quad  Mass Spectrometer) based on the assay described in Lin-
degardh  et al. [27]. (The individual samples were analysed only
once but assay robustness was  conﬁrmed by a re-analysis of
approximately  10% of all samples. Analytical runs included a
full calibration curve and three replicate quality control sam-
ples.)
The  assay has an associated lower limit of quantiﬁcation
(LLOQ) for each analyte and passed FDA validation, for which
the  requirement is to measure quality control samples and
standard  curve samples with known concentrations above the
respective  LLOQ to within ±15% of the nominal value. Specif-
ically,  the coefﬁcient of variation for the assay is 15% for both
analytes.  Values below the respective LLOQ may  have signif-
icantly  greater relative uncertainty or noise. The LLOQ for
ARS  was  LLOQ1 = 3.9 nmol/l and that of DHA was  LLOQ2 = 22.9
nmol/l.  The assumption is that values reported for unknown
samples  above the respective LLOQ will also be within 15%
of  the actual value. Observations below the respective LLOQ
are  felt to be so unreliable that such values are not quantiﬁed;
they  are only reported as being below the limit of quantiﬁca-
tion  (BLQ). In this way,  41% of the ARS data and 8% of the DHA
data  are censored.(1 if the assumption is applied and 0 if not) are either structurally
ly identiﬁable (G).
Note  that over the 12 h time span for a single subject, a wide
range  of drug concentrations was  observed, most particularly
for  DHA. Speciﬁcally, for DHA, concentrations smaller than
the  LLOQ and concentrations above 6000 nmol/l were  recorded
for  some patients over the course of the sampling interval. In
common  with other studies, there was also wide variability
between patients in terms of the concentration–time proﬁles
for  both ARS and DHA.
The  majority of the patients had peak ARS concentra-
tions within 1.5 h after drug administration (74%), and peak
DHA  concentrations within 2 h (63%). However, it was  already
clear  from the data that over half of the patients experienced
delayed or possibly double peaks in the concentration–time
proﬁles for both ARS and DHA. These are not thought to be
outliers  due to the assay validation, and the pattern is quite
consistent  in some individuals. There are no covariates with
these  data to allow further analysis and the cause of this
phenomenon is not known, nor the frequency of incidence
in  other artesunate studies as individual patient proﬁles are
often  not discernible. The only reference to this issue in rela-
tion  to artemisinin drugs that the authors are aware of is
to  the derivative artemether, which was  found by Van Agt-
mael  et al. [28] to have a biphasic absorption proﬁle. As the
mechanistic cause of the phenomenon is unknown, the dif-
ferences  in the absorption process have not been accounted
for  in the present model. This indicates that the model is mis-
speciﬁed  and will not be suitable for all the patients, though
it  is hoped that it will still be applicable for many  of the
patients.
The  patients were therefore divided into two groups, one
where  the concentration–time proﬁles for both ARS and
DHA  exhibited only a single peak each within the expected
time  after drug administration, and the other group for the
remaining  patients where the absorption proﬁle was  unex-
pected,  e.g. being slower to reach the peak concentrations,
having multiple peaks and/or having delayed elimination.
Model ﬁts and validation will therefore be separately described
for  each of the two groups.
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Fig. 2 – Example of observed ARS and DHA plasma concentrations (nmol/l) for three patients. Error bars represent ±15% of
the observations and are representative of the assay error (for reasons discussed in Section 4.2).
p
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h
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e
wFor illustration, consider Fig. 2. The concentration–time
roﬁles for both drugs for patient A were as expected, so this
atient  was  placed in the ﬁrst group. Patient B, however, clearly
as  an unusual concentration–time proﬁle (and it is not clear
hether  it is just caused by random measurement error) and
o  was  placed in the second group. The proﬁles for patient C
xhibited  later peaks (and thus delayed DHA elimination), and
as  also placed in the second group.4.2.  Statistical  treatment  of  data
At this stage, the structural model is now considered with
error  (for a single patient), and the observations are now
ﬁnite  in number and collected at discrete times. Only mea-
surement  error is considered, as error resulting from model
misspeciﬁcation is assumed to be dominated by measurement
error.
 m s i8  c o m p u t e r m e t h o d s a n d p r o g r a
So, let y˜i denote the ith observation of drug di (0 = ARS, 1
=  DHA) and ti denote the time at which this observation was
made.  Then,
y˜i = hi(p) + i,
where  hi(p) = max{ydi (p, ti), LLOQdi } is the model prediction of
the ith observation and i denotes the observation error (and
ydi is as in (1)).
Statistically,  it is assumed that the measurement error is
normally  distributed, so a measured value of y˜i is assumed
to  be an observation from a N(hi(p), 2i ) distribution where
i = ıhi(p) with ı = 0.15. Equivalently, i∼N(0, 2i ). It is further
assumed that the observation errors for observations at dif-
ferent  times are independent. (This assumption may  not be
realistic  but was  felt to be a good starting point in the absence
of  any prior information to the contrary.) Observation errors
for  ARS and DHA observations obtained at the same time
are  assumed to be correlated with correlation parameter 
unknown.
Note  that this error model does not account for the fact
that  the observed concentrations will always be positive, but
is  nevertheless convenient to work with.
Observations below the respective LLOQ may  be caused by
no  drug being present at all, the drug quantity being close to
the  LLOQ itself, or any range in between. Values below the
LLOQ  are treated as being at the LLOQ here, as this simpliﬁes
their  statistical treatment, and this method was  shown to pass
certain tests for suitability, described shortly.
It is convenient to view the y˜i as forming a one-dimensional
vector. Write y˜  for the data and h(p) for their model pre-
dictions. The above speciﬁcation gives rise to the following
log-likelihood function, deﬁned up to an additive arbitrary
constant:
(p|y˜) = −1
2
(log det V(p) + (y˜ − h(p))TV(p)−1(y˜ − h(p))︸  ︷︷  ︸
weighted residual sumof squares (WRSS)
), (11)
where V(p) is the weighting matrix with (i, i)-th element 2
i
and (i, j)-th element ij when ti = tj, i /=  j. Note that with this
deﬁnition, the residuals y˜i − hi(p) are zero for those points i
where  the model prediction and corresponding datum both
lie  below the LLOQ.
Similarly  to Bergstrand and Karlsson [29], this methodol-
ogy  was  ﬁrst tested on simulated data to determine how well
it  copes with the censored aspect. First, using simulated data
with  known parameter values, with and without censoring
and  error, model ﬁtting was  conducted to see how reliably and
closely  the original parameter values were  reproduced. This
included  omitting BLQ values from the ﬁtting, treating them
as  described above, and by assuming BLQ values are known
with  the same error distribution as the other data. Second,
real  data were  used with the above described procedure, and
by  omitting BLQ values, and the corresponding ﬁts compared.
In  each case, parameter estimates and ﬁtted curves did not sig-
niﬁcantly differ with the different methodologies. Further, in
the simulated data case, the original parameters were closely
recovered. n b i o m e d i c i n e 1 1 2 ( 2 0 1 3 ) 1–15
4.3.  Estimation  procedure  and  parameter  uncertainty
Standard numerical optimisation methods were used to ﬁnd
a  minimiser pˆ of the negative of the log-likelihood expres-
sion  (hereafter referred to as the objective function), and the
minimiser  was  used as an estimate of the parameters. See
e.g.  Seber and Wild [30]. This optimisation was  carried out in
Mathematica  using the NMinimize function.
To attempt to quantify the uncertainty in the parameter
estimates, the asymptotic (for a large number of observations)
distribution of the parameter estimates was found [30]. This
technique  is appropriate even if pˆ  is only a local minimiser of
the  objective function, rather than a global minimiser.
The asymptotic distribution of the parameter estimate pˆ
is  approximately MVN (p*, C) where MVN denotes the multi-
variate  normal family of distributions, p* is the “true” value
of  p and the variance-covariance matrix C is described next.
Consider  the linear approximation to the dependence of the
unweighted  residuals on the parameters about the estimate
pˆ:
R(pˆ) = ∂
∂pT
(y˜ −  h(p))|p=pˆ. (12)
The inverse of the Fisher information matrix at pˆ provides  an
estimate  C of the asymptotic variance-covariance matrix for
pˆ,
C = (R(pˆ)TV(pˆ)−1R(pˆ))−1. (13)
The variance-covariance matrix C is easier to interpret by
reporting  the diagonal elements of C together with the cor-
relation  matrix formed by dividing the respective rows and
columns  by the square roots of these diagonal elements. This
information  fully speciﬁes C but is easier to compare and con-
trast  than C itself.
4.4.  Goodness  of  ﬁt  statistics
Likelihood function values and WRSS values are not directly
comparable between patients, due to each data set having
a  different variation to begin with. Instead, the (weighted)
coefﬁcient of determination can be used. Loosely speaking, this
expresses  the variation in the data explained by the model as
a ratio of the total variation present in the data, and is deﬁned
as
R2:=100
(
1 − (y˜  − h(p))
TV(p)−1(y˜ − h(p))
(y˜ − y¯)TV(p)−1(y˜ − y¯)
)
%, (14)
where the elements of y are the average of the observed values
for  the corresponding curve.
The idea is that a larger coefﬁcient of determination should
indicate  a better ﬁt. However, a large value of this statistic
does  not necessarily correspond to a high likelihood, which
is  in some ways  problematic, but it does accord at least qual-
itatively  with a visual analysis of ﬁts. (Note that the baseline
model  is simply a mean model, which is not contained in the
ﬁtted  model class, so the ANOVA interpretation of this statistic
does  not apply.)
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Paramete r Fitte d valu e Standar d erro r Units
bα 0.2330 0.010 5 kg/l
r 4.3870 (fixed ) dimensionless
k21 1.2518 0.086 3 h
−1
k42 2.0378 0.019 9 h
−1
k43 0.4604 0.011 3 h
−1
ke4 0.9975 0.042 6 h
−1
ρ 0.0207 (nuisance ) correlation
Objecti ve functio n valu e 3747.23
%64.69noitanimretedfoCoefficient
Parameter correlatio n matri x (darknes s of bla ck/re d colou r corres pond s to strengt h of
positi ve/negati ve valu e in ea ch cel l res pecti vely):
bα k21 k42 k43 ke4
bα 1.000 −0.977 0.199 −0.767 0.994
k21 −0.977 1.000 −0.292 0.638 −0.982
k42 0.199 −0.292 1.000 −0.021 0.187
k43 −0.767 0.638 −0.021 1.000 −0.712
ke4 0.994 −0.982 0.187 −0.712 1.000
Fig. 3 – Example of model predicted ARS and DHA quantities/concentrations in each compartment for patient A, with table
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.5.  Results:  individual  ﬁts
ue to the wide range in concentrations reported for individ-
al  patients over the studied time interval, parameter ﬁtting
sing  the weighting matrix corresponding to the reported
rrors  did not yield good ﬁts. When using errors corresponding
o  predicted observations, high concentrations were artiﬁ-
ially  predicted, corresponding to low weights. These points
ould  thus be missed completely with little penalty on the
ikelihood.  Prior to conducting the analysis, this symptom
as  expected and it was  planned that the condition num-
er  of the weighting matrix might need to be controlled to
esolve  this. The singular values of the weighting matrix (toror bars are representative of assay error.
cater  for the cases where the matrix was not diagonal due
to  the assumption of correlation between different measure-
ment  errors) were therefore capped so that no singular value
exceeded  100 times the lowest singular value, resulting in
the  condition number of the weighting matrix becoming at
most  100. Imposing this cap yielded much  improved model
ﬁts.
Even  with this cap, the objective function had multiple
local minima for many  patients, and often had multiple local
minima  achieving similar objective function values but con-
siderably  different parameter estimates. In these cases, the
global  minimum was  usually selected, except in a minority of
cases  where the ﬁtted parameter values were  extreme and a
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Paramete r Fitte d valu e Standar d erro r Units
bα 0.6730 0.020 5 kg/l
r 4.3870 (fixed ) dimensionless
k21 0.1037 0.005 3 h
−1
k42 0.7568 0.010 4 h
−1
k43 0.3020 0.004 3 h
−1
ke4 1.8599 0.055 9 h
−1
ρ 0.1809 (nuisance ) correlation
Objecti ve functio n valu e 7372.58
%57.88noitanimretedfoCoefficient
Parameter correlatio n matri x (darknes s of bla ck/re d colou r corres pond s to strengt h of
positi ve/negati ve valu e in ea ch cel l res pecti vely):
bα k21 k42 k43 ke4
bα 1.000 −0.917 −0.681 0.245 0.989
k21 −0.917 1.000 0.754 −0.491 −0.935
k42 −0.681 0.754 1.000 −0.764 −0.739
k43 0.245 −0.491 −0.764 1.000 0.362
ke4 0.989 −0.935 −0.739 0.362 1.000
Fig. 4 – Example of model predicted ARS and DHA quantities/concentrations in each compartment for patient B, with table
ly, erof parameter estimates and their uncertainties. As previous
local minimum seemed more  realistic. This highlights the fact
that having a globally identiﬁable model structure is a neces-
sary  but not sufﬁcient condition to ensure robust parameter
estimation from sampled data, especially in the presence of
high  model and observation errors.
Observations and model ﬁts for the three patients whose
proﬁles  were shown previously are presented in Fig. 3
(patient  A), Fig. 4 (patient B) and Fig. 5 (patient C), together
with  model predictions of the quantities in the absorption
compartments, and estimated parameter values with meas-
ures  of their uncertainty. The conﬁdence bands give an
indication  of the sensitivity of the ﬁt and are explained and
discussed  in the following section.ror bars are representative of assay error.
It can be seen that the model ﬁt for patient A appears to
be  satisfactory. It is difﬁcult to determine whether the ﬁt for
patient  B is reasonable or not because the concentration–time
proﬁles observed are unusual, and may  or may  not be a result
of  random measurement error. The ﬁt for patient C is unsatis-
factory  because the model cannot account for the later peaks
due  to the model misspeciﬁcation mentioned earlier. The con-
ﬁdence bands for patient C also clearly indicate a problem with
the  model.For brevity, results for the other patients are not pre-
sented here in the same way,  but instead model ﬁt results
are  summarised through the coefﬁcient of determination and
shown  in Fig. 6, and a summary of parameter estimates
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Parameter Fitted value Standar d erro r Units
bα 0.3070 0.129 4 kg/l
r 4.3870 (fixed ) dimensionless
k21 0.1355 0.057 0 h
−1
k42 0.5420 0.030 6 h
−1
k43 0.6935 0.329 7 h
−1
ke4 0.7576 0.318 4 h
−1
ρ 0.0010 (nuisance ) correlation
Objective function value                  7945.91
%26.98determinationfoCoefficient
Paramete r correlatio n matri x (darkness of black/red colou r corres ponds to strengt h of
positive/negative value in ea ch cell res pectively):
bα k21 k42 k43 ke4
bα 1.000 −0.996 0.908 −0.997 1.000
k21 −0.996 1.000 −0.877 0.988 −0.996
k42 0.908 −0.877 1.000 −0.937 0.909
k43 −0.997 0.988 −0.937 1.000 −0.997
ke4 1.000 −0.996 0.909 −0.997 1.000
Fig. 5 – Example of model predicted ARS and DHA quantities/concentrations in each compartment for patient C, with table
of parameter estimates and their uncertainties. As previously, er
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Fig. 6 – Distribution of the coefﬁcient of determination (%)
over  the dataset; marks in red correspond to patients with
unexpected  proﬁles. Recall that the objective was  not to
maximise  the coefﬁcient of determination, but this statistic
allows  easier comparison between subjects than the actual
objective  function values.ror bars are representative of assay error.
across all patients is provided in Table 2. The worst model
ﬁts  correspond to patients whose observed ARS and DHA
concentration–time proﬁles did not both reach peaks within
3  h of dose administration, or those where at least one of
the  drugs exhibited multiple peaks (approximately half of the
patients  exhibited one of these issues, and are coloured in red
in Fig. 6). Note that the ﬁt for one such patient has a negative
coefﬁcient of determination. This does not necessarily sug-
gest  that ﬁtting the mean to the concentration–time proﬁle of
each  drug would have performed better than ﬁtting the model
(although  that is a natural interpretation), because the model
still  captures part of the absorption and elimination processes
and  therefore their shapes, though model predictions should
not  be relied upon in these circumstances. The coefﬁcient of
12  c o m p u t e r m e t h o d s a n d p r o g r a m s i
Table 2 – Fitted parameter values, aggregated
Parameter Mean (SD) Units
b  ˛ 0.4723 (0.3205) kg/l
r 4.3870 (ﬁxed) Dimensionless
k21 0.2806 (0.2987) h−1
k42 1.1185 (0.7436) h−1
k43 0.8347 (0.5908) h−1
ke4 1.6123 (1.2848) h−1CoD weighted 74.2505 (28.8048) %
ARS  half-life 0.9283 (0.5778) h
DHA half-life 0.7156 (0.5304) h
determination statistic was  used to help quantify the good-
ness  of the model ﬁts, but it is not without problems and
should  not be considered the sole determinant of the result.
The  ﬁts were  typically insensitive to the correlation param-
eter   (perhaps as a result of the weight cap) and this
parameter was  often ﬁtted close to 0 even when not used as
the  initial value for the optimisation. Having preferred a local
minimum  over the global minimum in some cases, no indi-
vidual  parameter estimates were unreasonable in isolation.
However, the parameter estimates were not always consid-
ered  well determined and many  varied signiﬁcantly between
patients.  This was  most marked for k21, where the largest and
smallest  estimated values differed by a factor of 100, while
the  other parameters varied by roughly a factor of 10. The wide
variability  in the patient proﬁles makes it possible that (though
unclear  whether) this is plausible, and could be due to differ-
ences  in the severity of the malaria, issues with the quality of
the  data, or other covariates (such covariates were not avail-
able  for evaluation here). These issues will be explored further
in  the following section, “Sensitivity analysis”.
Many  people working in the ﬁeld prefer to express elimina-
tion  parameters in terms of half-lives. From the parameters in
the parameter vector p, the ARS half-life can be calculated as
t 1
2 ,ARS
= ln 2/(k42 + ke2), (15)
and the DHA half-life as
t 1
2 ,DHA
= ln 2/ke4. (16)
Estimates of these parameters obtained here (shown in
Table  2) agree in range with those summarised in Morris et al.
[12]  (0.36–1.2 h for ARS and 0.49–3.08 h for DHA), but while Mor-
ris  et al. [12] report that the DHA half-life is consistently longer
than  that of ARS, the same result was  not found for all the
patients  in this study; the reasons for this are unclear.
Model ﬁtting was  also conducted by relaxing one con-
straint  at a time (still resulting in SGI model structures) to
assess  the effect on the parameter estimates. Doing so either
did  not signiﬁcantly alter the parameter estimates, or oth-
erwise  did not generally improve ﬁts visually (sometimes
making them appear noticeably worse), and only marginally
reduced the objective function values. The resulting estimates
for  some parameters were very close to their constrained
values in some cases, while in others, the parameter estimates
changed  signiﬁcantly and inconsistently, and their associ-
ated  uncertainties increased also. When this occurred, the
changes  propagated to the other parameters too (due to the n b i o m e d i c i n e 1 1 2 ( 2 0 1 3 ) 1–15
correlation), resulting in even wider variability of the param-
eters  between patients. These results therefore provide
evidence suggesting that the constraints imposed are as rea-
sonable  as could be hoped.
5.  Sensitivity  analysis
A sensitivity analysis was  also carried out to assess how well-
determined  the parameter estimates are (with the exception
of  the nuisance parameter ), and the effects of slight pertur-
bations  of parameters on model predictions. This informs on
how accurately it is possible to determine the parameters and
how  accurately it is necessary to determine them.
The statistical parameter correlation matrices reported
together with the parameter estimates contain sensitivity
information. They indicate by how much  changes in any given
parameter  will affect the other parameters if the ﬁts are to
remain  similar. Pairs of parameters which are highly cor-
related  and parameters with high standard errors may be
difﬁcult  to estimate numerically. Many pairs of the parame-
ters  have high correlations, with absolute values above 0.80,
and  this is one possible explanation for some of the issues
encountered with the parameter estimation described in the
previous  section.
The  ﬁtted parameters have an asymptotic multivariate
normal distribution centred around the ﬁtted values, with
variance  given approximately by the corresponding dispersion
matrix  (the matrix formed by the combination of the correla-
tions  and the standard errors), and this parameter distribution
gives  rise to distributions revealing the local uncertainty
around the ﬁtted curves. Monte Carlo techniques were  used
to  estimate the 10th and 90th percentiles of the latter distri-
butions,  and the regions between these two percentiles form
the  pointwise conﬁdence/prediction bands illustrated in the
plots.
While  it has already been noted that this model is not suit-
able  for all patients, particularly due to the issues with the
peaks,  in many  cases where the issue is prominent, the conﬁ-
dence  bands indicate that there is an issue with the model (as
observed for patient C).
A  further analysis was  also carried out using normalised
(ﬁrst-order) sensitivities, considering the whole time domain
of  interest instead of just the observational times as in the
statistical  results. The sensitivity of a dependent variable x
to  a change in the parameter pj (considered about parameter
vector pˆ) is the local quantity given by [31,32]
sx,pj := (
∂x
∂pj
)
∣∣∣∣
pˆ
,
but  for comparing between different parameters, the following
semi-normalised form is preferred [33]:
Sx,pj := (pj
∂x
∂pj
)
∣∣∣∣
pˆ
,which has the same units as x. Note that this formulation nor-
malises  only by the presence of the pj, and does not divide by
x  itself (unlike as in [31,32]) to facilitate interpretation in an
identiﬁability and correlation sense.
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Fig. 7 – Normalised sensitivity plots for the model about the estimated parameters for patient A, ﬁrst with respect to the
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Note that if the variable x is a function of an independent
ariable—such as time as here—then so are its sensitivities
Sx,pj ). It is therefore useful to summarise each as a single
alue, in addition to visualising them as graphical plots over
he  relevant domains. A natural summary is the mean of the
bsolute  value of the sensitivity function,
x,pj :=
1
12
∫ 12
0
|Sx,pj (t)|dt. (17)
If the shapes of curves (exclusive of direction and scale)
or  the sensitivities of multiple parameters are similar for
ll  observation variables, or if any parameters have low
ormalised sensitivities, numerical identiﬁability of those
arameters will be difﬁcult. In this case, if the curves for the
orresponding model predictions are not also similar, inability
o  identify the parameters numerically will have a signiﬁcant
ffect  on the predictions.
While  sensitivity depends on the estimated parameters
nd so is a local property, when applied to the model presented
ere,  the sensitivity for different patients at their respective
arameter estimates were  very similar in shape, only with dif-
erences in scale; therefore only patient A is reported in full
etail.  The graphical plots for the normalised sensitivities for
atient A are collected in Fig. 7 together with their means as
escribed  above. As the observation gain for the observed cir-
ulation  compartments does not have any relevance to the
redicted  quantities in the absorption compartments, notethat b  ˛ has no inﬂuence on the latter, which has to be con-
sidered  modulo the unidentiﬁable bioavailability factor b.
Recall from earlier that not all parameters were consid-
ered  well determined by the data for a number of patients.
This  can now be explored in more  depth. Subjects for which
such  issues were  observed had high standard deviation esti-
mates  for the problem parameter(s), and had corresponding
normalised sensitivities relating to the observed quantities an
order of magnitude lower than that shown for patient A. In
some  cases, when the observations are insensitive to a param-
eter,  the model predictions are similarly insensitive to it as
well.  Therefore, even though the parameter cannot be esti-
mated  to a high degree of conﬁdence in such circumstances,
it  is not necessary for it to be known with high precision to
maintain  model utility. On the other hand, there were  some
parameters to which the unobserved quantities were equally
or  more  sensitive than the observed quantities, and the model
is  of limited use when these parameters cannot be estimated
with  conﬁdence, such as in the case of patient C.
6.  Conclusion
A novel feature of the proposed model is that it accounts
for  the possibility that some of the orally administered
parent drug ARS is metabolised into DHA before it is com-
pletely  absorbed, e.g. as a ﬁrst-pass effect. This is consistent
with  previous reports in the literature. Just as the pharma-
cokinetics of ARS and DHA differ widely between individuals,
 m s i
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so too do the goodness of ﬁts and parameter estimates under
this  new model. Model ﬁts appeared to be reasonably good for
a number of patients, but the concentration–time proﬁles for
certain  patients did not ﬁt the usual absorption behaviour, and
model  ﬁtting was  less satisfactory for some of these patients.
The  authors are currently looking into those data sets
where  double peaks were apparent, and further investigation
is  also needed with more  extensive datasets. If this phe-
nomenon is observed elsewhere and conﬁrmed to be distinct
from  random measurement error, the authors would like to
determine a more  appropriate mechanistic model under these
circumstances. Future work also includes consideration of
optimal  design measures and performing a random effects
analysis  for the subjects—a kind of population analysis, where
parameters  are estimated using all individual data sets, allow-
ing  the parameters to borrow support across all individual
data  sets while still providing separate ﬁts for each individual
patient.
An  important inﬂuencing factor in the pharmacokinetics of
the  artemisinin drugs is the severity of the malaria infection
in  the subject. Speciﬁcally, the disposition and effectiveness
of  artemisinin drugs very much  depends on the number of
parasites  within each of the developmental forms (ring forms,
young  trophozoites, mature trophozoites and schizonts, etc.)
during  the therapeutic window, as each stage has a different
artemisinin susceptibility and the pharmacodynamic action
is  a route of elimination for these drugs. Reduced ring form
susceptibility is also thought to be an important effect of par-
asite  resistance to artemisinins [19]. Therefore, the authors are
currently investigating pharmacokinetic/pharmacodynamic
models incorporating the lifecycle of the parasites where the
drugs  affect the parasites and the parasites affect the drugs.
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